FDA’s Center for Veterinary Medicine (CVM) is responsible for ensuring that available drugs are safe and effective for their intended use in animals. Several offices at CVM are directly involved in reviewing and monitoring the safety and effectiveness of fish drugs:
The Office of New Animal Drug Evaluation is the lead office for reviewing information about animal drugs and determining if the information meets the approval requirements.
The Office of Minor Use and Minor Species Animal Drug Development manages programs and incentives that help the drug industry develop drugs for minor species, including fish, and make them legally available.
The Office of Surveillance and Compliance is the lead office for monitoring safety and effectiveness information about animal drugs after they are approved and on the market and also about marketed unapproved animal drugs. The office also recommends corrective or regulatory action when FDA identifies problems with an animal drug or regulatory violations.
The Office of Research develops methods and models to help FDA better ensure that food made from animals treated with an animal drug is safe for people to eat.